-
公开(公告)号：KR1020180094518A
公开(公告)日：2018-08-24
申请号：KR1020170007911
申请日：2017-01-17
Applicant: 한국화학연구원
CPC classification number: A61K9/00 , A61K9/10 , A61K9/16 , A61K47/56 , A61K9/0019
Abstract: 본발명은약물로서미세분말을담지하는생분해성고분자미립구서방출제제및 이러한서방출제제의제조방법에관한것이다. 상기서방출제제는약물이이온성고분자와복합체형태로생분해성고분자에봉입되어장기간동안방출을지연시키기위한약물-고분자이온복합체입자를포함한다. 본발명에따른제조방법은 S/O/W 용매내 추출증발법(Solid-in-Oil-in-Water; solvent intra extraction evaporation)을이용하여약물미세분말및 방출조절용약물-고분자이온복합체입자를생분해성고분자로제조된미립구에봉입하는것으로써간단한제조과정으로생산성을높일수 있으며, 미립구내 약물의봉입량과봉입효율을극대화하고, 초기과다방출을억제하며, 체내에서약물이 1달이상장기간에걸쳐지속적으로방출될수 있다.
-
公开(公告)号：KR101860932B1
公开(公告)日：2018-05-24
申请号：KR1020160066746
申请日：2016-05-30
Applicant: 한국화학연구원 , (주)씨에이치케미칼
IPC: A61K9/00 , A61K47/48 , A61K47/44 , A61K47/28 , A61K31/553
Abstract: 본발명은약물로네포팜(Nefopam) 또는이의약학적으로허용가능한염을함유하는조성물에관한것으로서, 사이클로덱스트린을사용하여용해도와담지율을높임과동시에인지질기반으로서방성을달성한조성물및 이러한조성물의제조방법에관한것이다. 본발명에따른제조방법은네포팜또는이의염과사이클로덱스트린이용해된산성용액과, (인)지질과중성오일이용해된유기용액를고속으로교반하여만든에멀전을다시수용액과제2에멀전을만들고, 유기용매를증발시켜서네포팜이담지된리포솜을형성하여서방출성을달성하는것을특징으로한다. 본발명에따른제조방법은간단한제조과정으로생산성을높일수 있다. 본발명에따른조성물에서는네포팜의초기과다방출이억제되며, 체내에서네포팜이일정기간동안지속적으로방출될수 있다.
-
公开(公告)号：KR1020160103207A
公开(公告)日：2016-09-01
申请号：KR1020150025072
申请日：2015-02-23
Applicant: 한국화학연구원
IPC: A61K9/107 , A61K9/00 , A61K47/48 , A61K31/192
CPC classification number: A61K9/1075 , A61K9/0002 , A61K31/192 , A61K47/6907
Abstract: 본발명은비스테로이드항염증제 10 내지 50 중량%; 옥시C알킬렌글리콜류용해제 3 내지 30 중량%; [폴리에틸렌옥사이드(PEO)-폴리프로필렌옥사이드(PPO)-폴리에틸렌옥사이드(PEO)] 형태의트리블록공중합체류 3 내지 30 중량%; 및폴리옥시에틸렌계계면활성제 2 내지 30 중량%;를함유하는비스테로이드항염증제가봉입된마이셀을함유하는경구제에관한것으로, 약물을안정하게수용액상에서가용화하여용출율을높히고, 용출시간을단축시킴으로써대상에게투여시체내약물의흡수율및 흡수속도가향상되는효과가있으므로, 비스테로이드항염증제함유경구제로유용하게사용할수 있다.
Abstract translation: 本发明涉及具有包封非甾体抗炎药物的胶束的口服制剂，其包含：10-50重量％的非甾体抗炎药; 3-30重量％的氧-C_2- -4-亚烷基二醇型溶剂; 3-30重量％的三嵌段[聚环氧乙烷（PEO） - 聚环氧丙烷（PPO） - 聚环氧乙烷（PEO）] - 基共聚物; 和2-30重量％的聚氧乙烯基表面活性剂。 因此，药物稳定地溶解在水溶液中以提高药物洗脱速度并缩短洗脱时间，结果提高了药物对受试者的药物吸收速度和吸收速度。 因此，具有包封本发明的非甾体抗炎药的胶束的口服制剂可有利地用作含有非甾体抗炎药的口服制剂。
-
34.发明授权
公开(公告)号：KR101561610B1
公开(公告)日：2015-10-22
申请号：KR1020130146061
申请日：2013-11-28
Applicant: 한국화학연구원
Abstract: 본발명은본 발명은난용성약물이봉입된리포좀나노입자를포함하는장기안정성이우수한약학적제제및 이의제조방법에관한것으로써,본발명에따른난용성약물이봉입된리포좀나노입자크기는 30-900 nm로이를포함하는약학적제제의용해도를향상시키고, 장기안정성이우수하므로, 약물의생체이용률을향상시킬수 있다. 또한, 상기약학적제제는용이한제조방법으로제조할수 있으므로안정성이필요한난용성약물에유용하게적용할수 있다.
-
公开(公告)号：KR1020110051006A
公开(公告)日：2011-05-17
申请号：KR1020090107648
申请日：2009-11-09
Applicant: 한국화학연구원 , 한국콜마홀딩스 주식회사
IPC: A61K9/107 , A61K36/185 , A61K47/44
CPC classification number: A61K9/1075 , A61K9/0053 , A61K36/22 , A61K47/44 , A61K47/6907
Abstract: PURPOSE: A method for preparing self-microemulsifying drug delivery system composition using mastic is provided to ensure effective antibacterial and antifungal activity. CONSTITUTION: A self-microemulsifying drug delivery system composition contains 10-30 weight% of mastic, 20-25 weight% of oil, 25-45 weight% of surfactant, and 25-45 weight% of cosurfactant. The oil is glyceryl, oleate, polyoxygolyceride, or heavy chain triglyceride. A method for preparing the self-microemulsifying drug delivery system composition comprises: a step of pulverizing the solid mastic; a step of solublizing the resulting mastic powder using the oil; and a step of adding co-surfactant and then surfactant.
Abstract translation: 目的：提供一种使用乳糖制备自微乳化药物递送系统组合物的方法，以确保有效的抗菌和抗真菌活性。 构成：自微乳化药物递送系统组合物包含10-30重量％的乳香，20-25重量％的油，25-45重量％的表面活性剂和25-45重量％的辅助表面活性剂。 油是甘油基，油酸酯，聚氧化甘油三酯或重链甘油三酯。 一种制备自微乳化药物递送系统组合物的方法包括：粉碎固体乳香的步骤; 使用油溶解所得的乳香粉末的步骤; 以及添加辅助表面活性剂和表面活性剂的步骤。
-
Patent Agency Ranking
公开(公告)号：KR100996975B1
公开(公告)日：2010-11-29
申请号：KR1020080019750
申请日：2008-03-03
Applicant: 한국화학연구원
Abstract: 본 발명은 혈류 내 순환시간을 증가시킨 단백질로 수식된 리포솜 및 이의 제조방법에 관한 것으로서, 더욱 상세하게는 생체적합성 단백질을 양이온성 리포솜 표면에 정전기적 상호인력으로 이온 결합시키고, 리포솜 표면에 결합된 단백질을 변성시켜 리포솜과의 결합력이 강화시킴으로써 리포솜이 혈류 내에서 순환할 때 혈장 내 단백질의 흡착을 방지하여 혈류 내에서 리포솜의 안정성을 강화하는 한편, 체내 순환시간을 증가시키는 리포솜 및 이의 제조방법에 관한 것이다.
단백질, 수식, 리포솜, 이온 결합, 체내 순환시간-
公开(公告)号：KR1020100031320A
公开(公告)日：2010-03-22
申请号：KR1020080090356
申请日：2008-09-12
Applicant: 한국화학연구원
CPC classification number: A61K47/42 , A61K9/1271 , A61K9/1277 , A61K31/663 , A61K38/12
Abstract: PURPOSE: A liposome with increases circulation time in blood is provided to suppress adsorption of a protein in blood by strengthening binding force of the protein and liposome. CONSTITUTION: A liposome having increased circulation time in blood is produced by binding a protein on the surface of liposome containing negative ionic lipid and denaturing the protein. The protein is selected from albumin, globulin, glutenin, prolamine, albunoid, nuclear protein, glycoprotein, phosphoprotein, lipoprotein, chromoprotein, and gelatin.
Abstract translation: 目的：提高血液循环时间增加的脂质体，通过加强蛋白质和脂质体的结合力来抑制血液中蛋白质的吸附。 构成：通过在含有负离子脂质的脂质体的表面上结合蛋白质并使蛋白质变性来产生具有增加血液循环时间的脂质体。 蛋白质选自白蛋白，球蛋白，谷蛋白，谷醇溶蛋白，类白蛋白，核蛋白，糖蛋白，磷蛋白，脂蛋白，色蛋白和明胶。
-
公开(公告)号：KR1020100025427A
公开(公告)日：2010-03-09
申请号：KR1020080084155
申请日：2008-08-27
Applicant: 한국화학연구원 , 알보젠코리아 주식회사
CPC classification number: A61K9/2086 , A61K9/20 , A61K47/50
Abstract: PURPOSE: A sustained release table containing talniflumate is provided to enhance the solubility of non-soluble talniflumate and to control the release rate. CONSTITUTION: A talniflumate sustained release table contains talniflumate as an active ingredient, a solubilizer, and a hydrophilic polymer for a sustained release. The solubilizer is sodium laurylsulfate, taurodeoxycholic acid, cholic acid, chenodeoxycholic acid, ursodeoxycholic acid, Tween class or span class. The hydrophilic polymer is cellulose, polyalkyleneoxide, alginate, polyvinylalcohol, polyvinylpyrolidone, polyalckylglycol, polydextrin, pectin, povidone, carbomer, or Eudragit. The talniflumate sustained release tablet is formulated in a double-layer with a core tablet. The surface of the sustained release tablet also contains a drug coating layer coated with a drug coating solution. The drug coating liquid is polyvinyl alcohol, polypropyleneglycol, acrylic acid copolymer, hydroxylrpopyl methylcellulose, hydroxypropylcellulose, methylcellulose, ethylcellulose, or cellulose acetate.
Abstract translation: 目的：提供含有脱铁酸盐的缓释片，以增强不溶性脱钛酸盐的溶解度并控制释放速率。 构成：脱氟酸缓释片含有脱硝酸盐作为活性成分，增溶剂和用于持续释放的亲水性聚合物。 增溶剂是月桂基硫酸钠，牛磺脱氧胆酸，胆酸，鹅脱氧胆酸，熊去氧胆酸，吐温类或跨度类。 亲水性聚合物是纤维素，聚环氧烷，藻酸盐，聚乙烯醇，聚乙烯吡咯烷酮，聚羟基乙二醇，聚糊精，果胶，聚维酮，卡波姆或Eudragit。 脱铁片缓释片配制成双层含芯片。 持续释放片剂的表面还含有涂覆药物包衣溶液的药物包衣层。 药物包衣液是聚乙烯醇，聚丙二醇，丙烯酸共聚物，羟基丙基甲基纤维素，羟丙基纤维素，甲基纤维素，乙基纤维素或乙酸纤维素。
-
公开(公告)号：KR1020090128918A
公开(公告)日：2009-12-16
申请号：KR1020080054901
申请日：2008-06-11
Applicant: 한국화학연구원
IPC: A61K9/22 , A61K9/52 , A61K31/505
CPC classification number: A61K9/2866 , A61K9/2813 , A61K9/282 , A61K9/286 , A61K31/517 , A61K33/20 , A61K2300/00
Abstract: PURPOSE: A sustained release containing alfuzosin HCl is provided to control drug release rate through control of kind and thickness of material and improve sustained release property. CONSTITUTION: A sustained release formulation containing alfuzosin comprises crystal core; a pharmacologically active ingredient layer containing alfuzosin HCl, water-insoluble polymer, water-soluble polymer or their mixture; a sustained release layer containing a sustained release film forming material; and a pharmaceutically active ingredient layer containing alfuzosin HCl and water-insoluble polymer, water-soluble polymer or their mixture.
Abstract translation: 目的：提供含有盐酸阿夫唑嗪的持续释放，以通过控制材料的种类和厚度来控制药物释放速率，并提高持续释放性能。 构成：含有阿夫唑嗪的缓释制剂包括晶核; 含有盐酸阿夫唑嗪，水不溶性聚合物，水溶性聚合物或其混合物的药理活性成分层; 含有缓释膜形成材料的持续释放层; 以及含有盐酸阿夫唑嗪和水不溶性聚合物，水溶性聚合物或其混合物的药物活性成分层。
-
公开(公告)号：KR1020080058041A
公开(公告)日：2008-06-25
申请号：KR1020060132082
申请日：2006-12-21
Applicant: 한국화학연구원
CPC classification number: A61K9/0002 , A61K9/1635 , A61K9/1652 , A61K9/167 , A61K9/1688 , A61K31/404
Abstract: A controlled release pellet including indapamide is provided to control release of a drug more delicately than a tablet including the indapamide and increase compliance of a patient by being able to be administered one time per day. A controlled release pellet including indapamide comprises: a crystalline core(A); a pharmacologically active ingredient layer(B) formed on the surface of the crystalline core and including a drug containing the indapamide and a binder consisting of a water-insoluble polymer and a water-soluble polymer; and a release layer(C) formed on the surface of the pharmacologically active ingredient layer and including a release-type film forming material. The pellet comprises at least one lipophilic material coating layer between the pharmacologically active ingredient layer and the release layer.
Abstract translation: 提供包含吲达帕胺的控释丸，以控制药物比包括吲达帕胺在内的片剂更精细的释放，并且通过每天可以一次给药来增加患者的依从性。 包含吲达帕胺的控释丸包括：晶核（A）; 在结晶核心的表面上形成药物活性成分层（B），并且包含含有吲达帕胺的药物和由不溶于水的聚合物和水溶性聚合物组成的粘合剂; 以及形成在药理活性成分层的表面上并具有剥离型成膜材料的剥离层（C）。 颗粒包含药理活性成分层和释放层之间的至少一个亲脂性材料包衣层。
-
-
-
-
-
-
-
-
-
Search Results
127
records
(took 0.034 seconds)
